Sanofi launches Toujeo® (insulin glargine 300 units/mL) DoubleStar™, the highest unit capacity basal insulin pen for adults with diabetes
- The high-capacity cartridge means that the pen may last longer than other basal insulin pens,[i],[ii],[iii],[iv],[v],[vi] potentially increasing patient convenience[vii]
GUILDFORD – 3 June 2019 – Sanofi announced today the launch of Toujeo® (insulin glargine 300 units/mL) DoubleStar™, a new long-acting insulin glargine injection pen recommended for adults with Type 1 or Type 2 diabetes mellitus, who require at least 20 units of basal insulin per day.[i] Delivering 2-160 units in a single injection, DoubleStar™ has the highest unit capacity of any basal insulin pen on the market.[i],[ii],[iii],[iv],[v],[vi] For patients requiring more than 20 units of insulin, DoubleStar™ will last longer compared to any other basal insulin pen.[i],[ii],[iii],[iv],[v],[vi]
Dr Mohamed Elnaggar, Associate Specialist of Diabetes and Endocrinology, University Hospitals of Morecambe Bay said: “Diabetes is a chronic disease which currently affects 3.8 million people in the UK and is rising each year. It has a huge impact on the person’s day-to-day life, so treatment convenience is extremely important and must not be underestimated, as it can be crucial for helping patients to manage their condition.”
Dr Mike Baxter, Medical Therapy Area Expert, Diabetes said: “At Sanofi, we have been developing insulin treatments for diabetes for close to a century, so our commitment to the patient community is steadfast. We are delighted that DoubleStar™ is now available in the UK as it has been developed with patients in mind, to support them to reach their treatment goals.”
DoubleStar™ is a disposable pre-filled pen containing up to 900 units of insulin glargine.[i] It has the highest unit capacity of any basal insulin pen on the market, providing from 2-160 units of insulin in a single injection.[i],[ii],[iii],[iv],[v],[vi]
DoubleStar™ is recommended for appropriate adult patients with diabetes mellitus who require at least 20 units of basal insulin per day.[i]
About Toujeo® (Insulin glargine 300 units/mL)
Toujeo (insulin glargine 300 units/mL) is a solution for injection that contains the active substance insulin glargine.[i] It is long-acting human insulin analogue indicated to improve glycaemic control in adults with Type 1 or Type 2 diabetes mellitus.[i] It is available in pre-filled SoloStar® and now DoubleStar™ pens.[i]
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Sanofi Media Relations Contact
Tel.: +44 7935 503 416
[i] EMC. Toujeo 300 units/ml SmPC. Available at https://www.medicines.org.uk/emc/product/6938/smpc. Last accessed May 2019.
[ii] Product Design Specification. Toujeo® DoubleStar™ (Updated February 2017).
[iii] Lantus® European Summary of Product Characteristics (Updated February 2019).
[iv] Tresiba® European Summary of Product Characteristics (Updated November 2018).
[v] Levemir® European Summary of Product Characteristics (Updated June 2018).
[vi] Abasaglar® European Summary of Product Characteristics (Updated March 2018).
[vii] Singh R, et al. Eur Endocrinol. 2018;14:47–51.
Job bag number: SAGB.TJO.19.05.0867 Date of preparation: May 2019